6-Oxaspiro[4.5]decan-8-ol | 29839-61-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 6-Oxaspiro[4.5]decan-8-ol
• CAS: 29839-61-0
• 化学式: C₉H₁₆O₂
• 分子量: 156.225
• InChiKey: UGOZCCCOINCWMR-UHFFFAOYSA-N

物化性质

• 沸点：
  240.47°C (rough estimate)
• 密度：
  0.9885 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-Oxaspiro[4.5]decan-8-ol 在 copper(l) iodide 、 ammonium acetate 、 溶剂黄146 、 pyridinium chlorochromate 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 、 甲苯 为溶剂， 反应 34.5h， 生成 2-[-9-(4-fluorophenyl)-6-oxaspiro[4.5]decan-9-yl]acetonitrile
  参考文献：
  名称：

  AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

  摘要：

  Provided are an azabicyclic substituted oxaspiro derivative, a preparation method therefor and a medical use thereof. Specifically, provided are compounds represented by formula (I) and formula (II) or pharmaceutically acceptable salts, stereoisomers or solvates thereof, and a preparation method therefor and an application thereof.

  公开号：

  US20230128062A1
• 作为产物：
  描述：

  3-丁烯-1-醇 、 环戊酮 在 硫酸 作用下， 以60.9 %的产率得到6-Oxaspiro[4.5]decan-8-ol
  参考文献：
  名称：

  AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

  摘要：

  Provided are an azabicyclic substituted oxaspiro derivative, a preparation method therefor and a medical use thereof. Specifically, provided are compounds represented by formula (I) and formula (II) or pharmaceutically acceptable salts, stereoisomers or solvates thereof, and a preparation method therefor and an application thereof.

  公开号：

  US20230128062A1

文献信息

• AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20230128062A1

  公开（公告）日：2023-04-27

  Provided are an azabicyclic substituted oxaspiro derivative, a preparation method therefor and a medical use thereof. Specifically, provided are compounds represented by formula (I) and formula (II) or pharmaceutically acceptable salts, stereoisomers or solvates thereof, and a preparation method therefor and an application thereof.